The effectiveness of IL-6 blockade, minimizing ROS and DJ-1 levels and preventing the progressive accumulation of mast cells in the mouse model, suggest that administration of anti-IL-6R, inhibition of IL-6-triggered signaling or both may be considered as an adjunctive therapeutic approach for aggressive mastocytosis. This evidence concerns the gene IL6 and mastocytosis.